Selected publications
- Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. Translational Oncology. 2020 Academic Article GET IT
- NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. Investigational New Drugs. 2020 Academic Article GET IT
-
Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.
Oncologist.
2020
Academic Article
GET IT
Times cited: 2 -
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
Nature Communications.
2019
Academic Article
GET IT
Times cited: 15 - Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. JNCCN Journal of the National Comprehensive Cancer Network. 2019 Academic Article GET IT
-
Phase 1/2 study of fractionated dose lutetium-177–labeled anti–prostate-specific membrane antigen monoclonal antibody J591 ( 177 Lu-J591) for metastatic castration-resistant prostate cancer.
Cancer.
2019
Academic Article
GET IT
Times cited: 9 -
Phase I trials of anti-ENPP3 antibody–drug conjugates in advanced refractory renal cell carcinomas.
Clinical Cancer Research.
2018
Academic Article
GET IT
Times cited: 8 -
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
European Journal of Cancer.
2018
Academic Article
GET IT
Times cited: 13 - A multidisciplinary approach for the management of earlier stage renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 2018 Review GET IT
- Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. 2017 Academic Article
-
Next-generation rapid autopsies enable tumor evolution tracking andgeneration of preclinical models.
JCO Precision Oncology.
2017
Academic Article
GET IT
Times cited: 16 -
Recommendations for the Management of Rare Kidney Cancers.
European Urology.
2017
Review
GET IT
Times cited: 21 -
Clonal evolution of chemotherapy-resistant urothelial carcinoma.
Nature Genetics.
2016
Academic Article
GET IT
Times cited: 109 -
Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma.
Journal of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 32 - Is underutilization of cytoreductive nephrectomy in patients with metastatic renal cancer contributing to inferior survival?. Journal of Clinical Oncology. 2016 Editorial Article GET IT
-
A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma.
Oncologist.
2016
Academic Article
GET IT
Times cited: 42 -
Prostate-specific membrane antigen is a potential antiangiogenic target in adrenocortical carcinoma.
Journal of Clinical Endocrinology and Metabolism.
2016
Academic Article
GET IT
Times cited: 10 -
Recent advances in the management of renal cell carcinoma.
F1000Research.
2016
Review
GET IT
Times cited: 5 -
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
Critical Reviews in Oncology and Hematology.
2015
Review
GET IT
Times cited: 21 -
Metastatic non-clear cell renal cell carcinoma: An evidence based review of current treatment strategies.
Frontiers in Oncology.
2015
Review
GET IT
Times cited: 26 -
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis.
Clinical Genitourinary Cancer.
2015
Academic Article
GET IT
Times cited: 28 -
Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
Clinical Genitourinary Cancer.
2013
Academic Article
GET IT
Times cited: 41 -
Systemic treatment options for untreated patients with metastatic clear cell renal cancer.
Seminars in Oncology.
2013
Review
GET IT
Times cited: 19 -
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Cancer.
2012
Academic Article
GET IT
Times cited: 87 -
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Investigational New Drugs.
2012
Academic Article
GET IT
Times cited: 70 -
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
Medical Oncology.
2011
Academic Article
GET IT
Times cited: 7 -
Sarcomatoid-variant renal cell carcinoma: Treatment outcome and survival in advanced disease.
American Journal of Clinical Oncology: Cancer Clinical Trials.
2011
Academic Article
GET IT
Times cited: 61 -
MTOR inhibitors in advanced renal cell carcinoma.
Hematology/Oncology Clinics of North America.
2011
Review
GET IT
Times cited: 76 -
Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.
Oncologist.
2011
Review
GET IT
Times cited: 60 -
Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression.
Cancer Research.
2010
Academic Article
GET IT
Times cited: 19 -
Targeting renal cell carcinoma.
Journal of Clinical Oncology.
2009
Editorial Article
GET IT
Times cited: 48 - Efficacy and safety of everolimus treatment in metastatic renal cell carcinoma. American Journal of Oncology Review. 2009 Comment
-
Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma.
Clinical Genitourinary Cancer.
2008
Review
GET IT
Times cited: 30 -
Rare T-cell lymphomas.
Cancer treatment and research.
2008
Review
GET IT
Times cited: 1